PSS29 SOCIETAL COSTS OF SEVERE CHRONIC HAND ECZEMA (CHE) IN GERMANY
Hieke K 1 , Diepgen T 2 1 NEOS Health, Binningen, Switzerland, 2 University Hospital Heidelberg, Heidelberg, Germany OBJECTIVES: Severe chronic CHE is underreported in Germany. Reported data refer to work-related disease only and even these are incomplete (Diepgen & Schmidt 2002) . However, CHE has a huge impact on the working capacity of patients. We therefore targeted to estimate the total costs of severe CHE in Germany using epidemiological data in addition to reported cases of occupational CHE. METHODS: In a first step data on 151 patients with occupational CHE were analyzed to obtain information on direct and indirect costs of CHE. In a second step epidemiological information was used to create three groups of patients: 1) DGUV-patients (German Statutory Accident Insurance, payer for work-related diseases/accidents); 2) non-DGUV but full-time working patients and 3) non-DGUV, non-full time working patients. Cost assumptions per group were adjusted to reflect differing reimbursement catalogues (DGUV vs. Statutory Sick Funds), impact of work absenteeism and employment status.
Extensive scenario analyses with varying assumptions on costs and epidemiology were conducted. RESULTS: Group 1 included 23,631 patients, group 299,735 and group 3,115,253. Per patient costs per group amounted to €8799 in group 1, €5341 in group 2 and €1035 in group 3. This results in total societal costs of €860 million for severe, chronic CHE in Germany. Scenario analyses showed a range of €348 million to €1.59 billion. 67% of total costs were indirect costs, Statutory Sick Funds were the payer for 15.5%, patients for 11.5% and DGUV for 6%. CON-CLUSIONS: Total annual societal costs of severe chronic CHE are enormous, despite the fact that CHE is not a life-threatening disease. These costs are similar to the total costs of psoriasis, colon or stomach cancer in Germany. The main cost component are indirect costs. Effective therapeutic or preventive measures would have a huge potential for cost savings. Cataract is the principal cause of blindness worldwide and surgery is the only effective treatment for this condition. Several multifocal intraocular lenses (MFIOL) are currently available to reduce or eliminate the need for eyeglasses after surgery. The objective of this survey was to collect data in the Netherlands on the associated costs to society of wearing spectacles after cataract surgery. This,information was requested to support a health economics evaluation of MFIOLs. METHODS: Cross-sectional survey of centers that recruited patients who wore spectacles after cataract surgery and agreed to complete a questionnaire. RESULTS: Forty-seven patients were recruited with a mean age of 74.2 years and sex-ratio 2 females: 1 male. On average, they underwent cataract surgery 2.1 years prior to recruitment. A total of 97.9% had a private insurance which covered spectacle cost, at least partially, in 69.0% of the cases. Spectacles were prescribed by an optometrist for 48.9%, and glasses were multi focal in 76.7% of the cases (varifocal 44.7%). Spectacles were changed within 3 years in 50.0% of the patients. Patients live an average of 11.5 km from their ophthalmologist and 5.8 k from their opticians. Mean spectacle cost was €586.5, 43.7% being paid by private insurance. More than 80% of the patients wear glasses for watching TV, near reading, going to movies or theater, driving, walking outside and visiting friends. Dissatisfaction with glasses was rather rare at 13.7% of the patients; 47.6% of the subjects expressed some willingness to pay (at least €0.5 per day) to avoid wearing spectacles. CON-CLUSIONS: Although almost half of all subjects had a private health insurance, a large part of the cost was borne by patients. The total economic burden of spectacles was not limited to the spectacles; repeated travel related to eye care should also be considered. There is some willingness to pay to be free of spectacles in this population.
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